近日，国际权威医药行业媒体《Life Sciences Review APAC》揭晓年度评选结果，凯莱英生物（Asymbio）凭借全球领先的一站式生物药 CDMO 综合服务能力，被独家评为"Integrated Biologics CDMO Company of the Year in APAC 2026"，同时入选" 亚太地区 TOP CDMO" 榜单，进一步印证凯莱英生物在生物药 CDMO 的服务能力。

《Life Sciences Review APAC》（《亚太生命科学评论）是一本聚焦亚太生命科学领域的行业杂志。该奖项是亚太生物制药领域极具行业公信力与含金量的权威荣誉，旨在表彰在生命科学领域技术创新、生物医药服务、全球合规质量体系、商业化交付与行业影响力等各方面表现卓越的领军企业。

凯莱英生物 CEO 杨蕊在接受《Life Sciences Review APAC》专访时表示：

" 依托 AccPCC 早研服务平台与一站式 CDMO 服务，我们可在生物药全生命周期开发过程中，统筹兼顾管线和技术的前瞻性、项目进度与风险管理以及商业化进程中的关键节点，助力客户加速推进项目进入临床阶段并实现商业化落地。"

依托集团协同优势，凯莱英生物打造端到端生物药 CDMO一站式服务体系，覆盖抗体 & 蛋白、ADC&NDC 等新一代生物药，贯穿从候选分子评估、工艺开发、生产制造到法规申报的全流程。

通过AccPCC 早研服务平台打通早研、非临床与临床链路，上海金山、奉贤双基地形成双产能布局，满足从早期研发、毒理批次、临床样品到商业化大规模生产的需求。这套一体化的服务体系，能够规避多供应商交接引发的项目风险和进度延误，质量管理体系符合 NMPA、FDA、EMA 等全球药监规范和要求。更为重要的一点是，无论是早期研发服务还是 CDMO 服务，项目知识产权全部归属客户。

荣誉加冕，步履不停。未来，凯莱英生物将持续完善一体化技术与服务体系，深耕新一代生物药 CDMO，赋能全球生物药创新，加速前沿疗法落地，惠及全球患者。

《Life Sciences Review APAC 》 ( print ISSN 2831-8323 | digital ISSN 2831-8331 ) is an industry magazine focused on the Asia-Pacific life sciences sector. Its awards are a highly credible and prestigious honor in the Asia-Pacific biopharmaceutical industry, recognizing leading enterprises that demonstrate excellence in technological innovation, capacity and scale, regulatory compliance, commercial delivery, and industry influence.

In an exclusive interview with《Life Sciences Review APAC 》,Rui Yang, CEO of AsymBio, stated:

"Leveraging our integrated CDMO service model and AccPCC early-stage R&D acceleration platform, we take a holistic approach to forward-looking pipeline planning and advanced technologies, project timelines and risk management, and critical milestones on the path to commercialization. By supporting programs throughout the biologics development lifecycle, we help clients accelerate clinical progression and advance toward successful commercialization."

Leveraging the synergistic advantages of the group,AsymBiohas built an end-to-end, one-stopbiologics CDMOservice covering the full value chain of next-generation biologics — from antibodies and bispecific antibodies to ADCs — spanning candidate molecule assessment, process development, sample production, and regulatory filing.

Through theAccPCC early-stage research platform, we bridgeearly-stage research, non-clinical, and clinicaldevelopment. Ourdual-site manufacturing layout in Jinshan and Fengxian, Shanghai, provides dual capacity to meet demands ranging from early-stage R&D, toxicology batches, and clinical samples to commercial-scale manufacturing. This integrated service system mitigates project risks and timeline delays associated with multi-vendor handovers. Ourquality management systemcomplies with global regulatory requirements including NMPA, FDA, and EMA. More importantly, whether for early-stage research services or CDMO services,all project intellectual property rights are fully retained by the client.

This recognition spurs AsymBio onward. Looking ahead, AsymBio will continue to fortify its integrated technology platform and capacity system, deepen its focus on the development and manufacturing of next-generation biologics, empower global innovative pharmaceutical companies, and accelerate the R&D-to-clinic translation of cutting-edge biologics — so that innovative therapies can reach patients worldwide at the earliest possible time.